Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
CHUYÊN ĐỀ Issue: Số 106 năm 2023

Pharmacogenomics (PGx) in lipid-lowering therapies

Lương Thị Lan Anh: Trường Đại học Y Hà Nội;
Published: August 1, 2023
Views: 98
DOI 10.58354/jvc.106.2023.474

Abstract

This review presents an overview of pharmacogenomics and pharmacogenetics in clinical practice (PGx) to pharmacogenomics in lipid-lowering therapies. Statins are the first-line choice in Lipid-lowering therapy to reduce cardiovascular risk, then Non-Statin Lipid-Lowering Therapies and Novel Lipid-Lowering Therapies. The purpose of this review was to introduce the genomic variations in pharmacodynamics and pharmcokinetics of lipid-lowering drugs. Loss-of-function and gain-of-function variants significantly affect metabolism and transport. It is evidence to choose the right drug anh the appropriate dose. Common pharmacogenomics in lipid-lowering therapies are ABCG2, CYP3A4, HMGCR, LDLR, SLCO1B1, etc. FDA recommends testing pharmacogenomics in the clinical practice, and online reference information at PhamGKB. Physicians can search and consult the clinical practice guidelines for testing and using pharmacogenomics from international organizations such as CPIC (American), DPWG (Holand), etc.

References

1.
Najmeh Ahangari, Mohammad Doosti, Majid Ghayour Mobarhan, Amirhossein Sahebkar, Gordon A. Ferns & Alireza Pasdar. Personalised medicine in hypercholesterolaemia: the role of pharmacogenetics in statin therapy. Annals of Medicine: 2020, 52:8, 462-470.
2.
Nagham N. Hindi 1,†, Jamil Alenbawi 1,† and Georges Nemer. Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia. 2021, 11, 877.
3.
Alfonsi JE, Hegele RA, Gryn SE. Pharmacogenetics of lipid-lowering agents: precision or indecision medicine? Curr Atheroscler Rep. 2016;18(5):24.
4.
Mach F, Baigent C, Catapano AL, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1): 111-188.
5.
Mitchell D, Guertin JR, Iliza AC, et al. Economic evaluation of a pharmacogenomics test for statin-induced myopathy in cardiovascular high-risk patients initiating a statin. Mol Diagn Ther. 2017;21(1):95-105.
6.
Kitzmiller JP, Mikulik EB, Dauki AM, et al. Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016;9:97-106.
7.
Poduri A, Khullar M, Bahl A, et al. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA and Cell Biology. 2010;29(10): 629-637.
8.
Tornio A, Vakkilainen J, Neuvonen M, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenet Genomics. 2015; 25(8):382-387.
9.
Kozyra M, Ingelman-Sundberg M, Lauschke VM. Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. Genet Med. 2017;19(1):20-29.
10.
Ingelman-Sundberg M, Mkrtchian S, Zhou Y, et al. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum Genomics. 2018;12(1):26.
11.
Rubino, J.; MacDougall, D.E.; Sterling, L.R.; Hanselman, J.C.; Nicholls, S.J. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial. Atherosclerosis 2021, 320, 122-128.
12.
Kuehn, B.M. Evinacumab Approval Adds a New Option for Homozygous Familial Hypercholesterolemia with a Hefty Price Tag. Circulation 2021, 143, 2494-2496.
13.
Wang, L.; Muthuramu, I.; Somanathan, S.; Zhang, H.; Bell, P.; He, Z.; Yu, H.; Zhu, Y.; Tretiakova, A.P.; Wilson, J.M. Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemia. Mol. Ther. Methods Clin. Dev. 2021, 22, 1-10.
14.
Reeskamp, L.F.; Kastelein, J.J.P.; Moriarty, P.M.; Duell, P.B.; Catapano, A.L.; Santos, R.D.; Ballantyne, C.M. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2019, 280, 109-117.
15.
Hopkins, P.N.; Krempf, M.; Bruckert, E.; Donahue, S.; Yang, F.; Zhang, Y.; DiCioccio, A.T. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations. J. Clin. Lipidol. 2019, 13, 970-978.
16.
Brandts, J.; Dharmayat, K.I.; Vallejo-Vaz, A.J.; Azar Sharabiani, M.T.; Jones, R.; Kastelein, J.J.P.; Raal, F.J.; Ray, K.K. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis 2021, 325, 46-56.
17.
Hayat, M.; Kerr, R.; Bentley, A.R.; Rotimi, C.N.; Raal, F.J.; Ramsay, M. Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. PLoS ONE 2020, 15, e0229098, Correction in 2021, 16, e0249478.
18.
Borges, J.B.; Oliveira, V.F.; Ferreira, G.M.; Los, B.; Barbosa, T.; Marcal, E.; Dagli-Hernandez, C.; de Freitas, R.C.C.; Bortolin, R.H.; Mori, A.A.; et al. Genomics, epigenomics and pharmacogenomics of familial hypercholesterolemia (FHBGEP): A study protocol. Res. Soc. Adm. Pharm. 2021, 17, 1347-1355.
19.
Chahine, J.; Kreykes, S.; Van’t Hof, J.R.; Duprez, D.; Nijjar, P. Variable and Severe Phenotypic Expression of the “Lebanese Allele” in Two Sisters with Familial Hypercholesterolemia. Vasc. Health Risk Manag. 2021, 17, 415-419.
20.
Carr, D.F.; Francis, B.; Jorgensen, A.L.; Zhang, E.; Chinoy, H.; Heckbert, S.R.; Bis, J.C.; Brody, J.A.; Floyd, J.S.; Psaty, B.M.; et al. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clin. Pharm. Ther. 2019, 106, 1353-1361.
21.
Mangravite, L.M.; Medina, M.W.; Cui, J.; Pressman, S.; Smith, J.D.; Rieder, M.J.; Guo, X.; Nickerson, D.A.; Rotter, J.I.; Krauss, R.M. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arter. Thromb. Vasc. Biol. 2010, 30, 1485–1492.

Files

PDF
Article Views98
Document Views4
Downloads0
Section CHUYÊN ĐỀ
Issue Số 106 năm 2023